Clinical Endoscopy

  • 제57권1호
  • /
  • Pages.112-121
  • /
  • 2024
  • /
  • 2234-2400(pISSN)
  • /
  • 2234-2443(eISSN)
대한소화기내시경학회 (The Korean Society of Gastrointestinal Endoscopy)
권호 표지
DOI QR코드

DOI QR Code

Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer

  • Kunio Kataoka (Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine) ;
  • Eizaburo Ohno (Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine) ;
  • Takuya Ishikawa (Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine) ;
  • Kentaro Yamao (Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine) ;
  • Yasuyuki Mizutani (Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine) ;
  • Tadashi Iida (Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine) ;
  • Hideki Takami (Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine) ;
  • Osamu Maeda (Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine ) ;
  • Junpei Yamaguchi (Department of Surgical Oncology, Nagoya University Graduate School of Medicine) ;
  • Yukihiro Yokoyama (Department of Surgical Oncology, Nagoya University Graduate School of Medicine) ;
  • Tomoki Ebata (Department of Surgical Oncology, Nagoya University Graduate School of Medicine) ;
  • Yasuhiro Kodera (Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine) ;
  • Hiroki Kawashima (Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine)
  • 투고 : 2022.10.31
  • 심사 : 2022.12.23
  • 발행 : 2024.01.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Since the usefulness of neoadjuvant chemo(radiation) therapy (NAT) for pancreatic cancer has been demonstrated, recurrent biliary obstruction (RBO) in patients with pancreatic cancer with a fully covered self-expandable metal stent (FCSEMS) during NAT is expected to increase. This study investigated the impact of sarcopenia on RBO in this setting. Methods: Patients were divided into normal and low skeletal muscle index (SMI) groups and retrospectively analyzed. Patient characteristics, overall survival, time to RBO (TRBO), stent-related adverse events, and postoperative complications were compared between the two groups. A Cox proportional hazard model was used to identify the risk factors for short TRBO. Results: A few significant differences were observed in patient characteristics, overall survival, stent-related adverse events, and postoperative complications between 38 patients in the normal SMI group and 17 in the low SMI group. The median TRBO was not reached in the normal SMI group and was 112 days in the low SMI group (p=0.004). In multivariate analysis, low SMI was the only risk factor for short TRBO, with a hazard ratio of 5.707 (95% confidence interval, 1.148-28.381; p=0.033). Conclusions: Sarcopenia was identified as an independent risk factor for RBO in patients with pancreatic cancer with FCSEMS during NAT.

키워드

참고문헌

  1. Motoi F, Kosuge T, Ueno H, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol 2019;49:190-194.  https://doi.org/10.1093/jjco/hyy190
  2. Unno M, Hata T, Motoi F. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis. Surg Today 2019;49:295-299.  https://doi.org/10.1007/s00595-019-01786-w
  3. Yamaguchi J, Yokoyama Y, Fujii T, et al. Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01). Ann Surg 2022;275:1043-1049.  https://doi.org/10.1097/SLA.0000000000005430
  4. Aadam AA, Evans DB, Khan A, et al. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study. Gastrointest Endosc 2012;76:67-75.  https://doi.org/10.1016/j.gie.2012.02.041
  5. Kubota K, Sato T, Watanabe S, et al. Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer. Dig Endosc 2014;26:77-86.  https://doi.org/10.1111/den.12049
  6. Gardner TB, Spangler CC, Byanova KL, et al. Cost-effectiveness and clinical efficacy of biliary stents in patients undergoing neoadjuvant therapy for pancreatic adenocarcinoma in a randomized controlled trial. Gastrointest Endosc 2016;84:460-466.  https://doi.org/10.1016/j.gie.2016.02.047
  7. Nakamura K, Sho M, Akahori T, et al. A comparison between plastic and metallic biliary stent placement in patients receiving preoperative neoadjuvant chemoradiotherapy for resectable pancreatic cancer. World J Surg 2019;43:642-648.  https://doi.org/10.1007/s00268-018-4820-6
  8. Kuwatani M, Nakamura T, Hayashi T, et al. Clinical outcomes of biliary drainage during a neoadjuvant therapy for pancreatic cancer: metal versus plastic stents. Gut Liver 2020;14:269-273.  https://doi.org/10.5009/gnl18573
  9. Hasegawa S, Kubota K, Yagi S, et al. Covered metallic stent placement for biliary drainage could be promising in the coming era of neoadjuvant chemo-radiation therapy for all pancreatic cancer. J Hepatobiliary Pancreat Sci 2021;28:617-624.  https://doi.org/10.1002/jhbp.958
  10. Hamada T, Isayama H, Nakai Y, et al. Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. Gastrointest Endosc 2011;74:548-555.  https://doi.org/10.1016/j.gie.2011.04.046
  11. van Boeckel PG, Steyerberg EW, Vleggaar FP, et al. Multicenter study evaluating factors for stent patency in patients with malignant biliary strictures: development of a simple score model. J Gastroenterol 2011;46:1104-1110.  https://doi.org/10.1007/s00535-011-0383-0
  12. Nakai Y, Isayama H, Mukai T, et al. Impact of anticancer treatment on recurrent obstruction in covered metallic stents for malignant biliary obstruction. J Gastroenterol 2013;48:1293-1299.  https://doi.org/10.1007/s00535-013-0749-6
  13. Koya Y, Shibata M, Oe S, et al. Impact of sarcopenia on recurrent biliary obstruction after insertion of self-expandable metallic stent in patients with malignant biliary obstruction. J Hepatobiliary Pancreat Sci 2021;28:572-580.  https://doi.org/10.1002/jhbp.970
  14. Nishikawa H, Shiraki M, Hiramatsu A, et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res 2016;46:951-963.  https://doi.org/10.1111/hepr.12774
  15. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-213.  https://doi.org/10.1097/01.sla.0000133083.54934.ae
  16. Isayama H, Hamada T, Yasuda I, et al. TOKYO criteria 2014 for transpapillary biliary stenting. Dig Endosc 2015;27:259-264.  https://doi.org/10.1111/den.12379
  17. Seo DW, Sherman S, Dua KS, et al. Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial. Gastrointest Endosc 2019;90:602-612.  https://doi.org/10.1016/j.gie.2019.06.032
  18. Saito K, Nakai Y, Isayama H, et al. A prospective multicenter study of partially covered metal stents in patients receiving neoadjuvant chemotherapy for resectable and borderline resectable pancreatic cancer: BTS-NAC Study. Gut Liver 2021;15:135-141.  https://doi.org/10.5009/gnl19302
  19. Dumonceau JM, Tringali A, Papanikolaou IS, et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline: updated October 2017. Endoscopy 2018;50:910-930.  https://doi.org/10.1055/a-0659-9864
  20. Kawashima H, Hashimoto S, Ohno E, et al. Comparison of 8- and 10-mm diameter fully covered self-expandable metal stents: a multicenter prospective study in patients with distal malignant biliary obstruction. Dig Endosc 2019;31:439-447.  https://doi.org/10.1111/den.13366
  21. Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review: report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 2014;43:748-759.  https://doi.org/10.1093/ageing/afu115
  22. Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020;21:300-307.  https://doi.org/10.1016/j.jamda.2019.12.012
  23. Ohara M, Suda G, Kimura M, et al. Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. Hepatol Res 2020;50:715-725.  https://doi.org/10.1111/hepr.13499
  24. Okumura S, Kaido T, Hamaguchi Y, et al. Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Surgery 2015;157:1088-1098.  https://doi.org/10.1016/j.surg.2015.02.002
  25. Okumura S, Kaido T, Hamaguchi Y, et al. Impact of the preoperative quantity and quality of skeletal muscle on outcomes after resection of extrahepatic biliary malignancies. Surgery 2016;159:821-833.  https://doi.org/10.1016/j.surg.2015.08.047
  26. Shintakuya R, Uemura K, Murakami Y, et al. Sarcopenia is closely associated with pancreatic exocrine insufficiency in patients with pancreatic disease. Pancreatology 2017;17:70-75.  https://doi.org/10.1016/j.pan.2016.10.005
  27. Iglesia D, Avci B, Kiriukova M, et al. Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis. United European Gastroenterol J 2020;8:1115-1125.  https://doi.org/10.1177/2050640620938987
  28. Dominguez-Munoz JE, de la Iglesia-Garcia D, Nieto-Garcia L, et al. Endoscopic pancreatic drainage improves exocrine pancreatic function in patients with unresectable pancreatic cancer: a double-blind, prospective, randomized, single-center, interventional study. Pancreas 2021;50:679-684.  https://doi.org/10.1097/MPA.0000000000001817
  29. Leitzmann MF, Giovannucci EL, Rimm EB, et al. The relation of physical activity to risk for symptomatic gallstone disease in men. Ann Intern Med 1998;128:417-425.  https://doi.org/10.7326/0003-4819-128-6-199803150-00001
  30. Serra-Prat M, Mans E, Palomera E, et al. Gastrointestinal peptides, gastrointestinal motility, and anorexia of aging in frail elderly persons. Neurogastroenterol Motil 2013;25:291. 
  31. Nishikawa H, Shiraki M, Hiramatsu A, et al. Reduced handgrip strength predicts poorer survival in chronic liver diseases: a large multicenter study in Japan. Hepatol Res 2021;51:957-967.  https://doi.org/10.1111/hepr.13679
  32. Bundred JR, Kamarajah SK, Hammond JS, et al. Prehabilitation prior to surgery for pancreatic cancer: a systematic review. Pancreatology 2020;20:1243-1250.  https://doi.org/10.1016/j.pan.2020.07.411
  33. Nakajima H, Yokoyama Y, Inoue T, et al. Clinical benefit of preoperative exercise and nutritional therapy for patients undergoing hepato-pancreato-biliary surgeries for malignancy. Ann Surg Oncol 2019;26:264-272. https://doi.org/10.1245/s10434-018-6943-2